Novartis (NVS)
(Delayed Data from NYSE)
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$113.86 USD
-0.09 (-0.08%)
Updated Oct 7, 2024 04:00 PM ET
After-Market: $113.88 +0.02 (0.02%) 7:58 PM ET
3-Hold of 5 3
B Value D Growth A Momentum B VGM
Zacks News
Immunome (IMNM) Surges on Merger Agreement With Morphimmune
by Zacks Equity Research
Immunome's (IMNM) shares rise following its announcement to merge with Morphimmune. The synergy will help strengthen the development of oncology therapies.
Bristol Myers' (BMY) Opdivo With Chemo Gets EC Nod for NSCLC
by Zacks Equity Research
Bristol Myers' (BMY) Opdivo, in combination with chemotherapy, gains European Commission approval for neoadjuvant treatment of non-small cell lung cancer, offering new hope for reducing recurrence risk.
Sigilon (SGTX) Skyrockets 441% on Buyout Offer From Eli Lilly
by Zacks Equity Research
Eli Lilly (LLY) is set to acquire Sigilon (SGTX) for $14.92 per share, in cash, along with a contingent value right of $111.64 per share.
Esperion (ESPR) to Expand Nilemdo and Nustendi Label in Europe
by Zacks Equity Research
Esperion (ESPR) files type II(a) variation application for expanded use of Nilemdo and Nustendi in Europe to reduce cardiovascular risk.
Axsome (AXSM) Down on Public Offering of Common Stock
by Zacks Equity Research
Axsome (AXSM) is set to issue secondary shares, which will significantly dilute its current shareholder base. Consequently, share price declines.
Sanofi (SNY) Atopic Dermatitis Drug Meets Goals in Phase II Study
by Zacks Equity Research
Sanofi's (SNY) phase II study, investigating amlitelimab for moderate-to-severe atopic dermatitis in adults, meets the primary endpoint.
Amicus (FOLD) Gets Approval in Europe for Pompe Disease Drug
by Zacks Equity Research
Amicus (FOLD) receives approval for Opfolda (miglustat) from the European Commission to treat the adult late-onset Pompe disease.
Agios' (AGIO) Sickle Cell Disease Study Meets Primary Endpoint
by Zacks Equity Research
Agios' (AGIO) mid-stage, label expansion study of mitapivat meets its primary endpoint. The data from the study supports AGIO's decision to proceed with the phase III portion of the investigation.
FibroGen (FGEN) Plunges on Failure of Late-Stage IPF Study
by Zacks Equity Research
FibroGen (FGEN) plummets on yet another pipeline setback. The phase III study, ZEPHYRUS-1, evaluating the safety and efficacy of pamrevlumab in patients with idiopathic pulmonary fibrosis fails to meet goals.
Bristol Myers (BMY) Heart Drug Camzyos Wins EC Approval
by Zacks Equity Research
Bristol Myers (BMY) receives EC approval for Camzyos for treating symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (HCM) in adult patients.
NVS or LLY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
NVS vs. LLY: Which Stock Is the Better Value Option?
Pfizer (PFE) Stock Down on Halting Development of Obesity Drug
by Zacks Equity Research
Shares of Pfizer's (PFE) fell 3.7% on Monday after management's decision to terminate the development of an experimental obesity pill following concerns over liver safety.
GSK's (GSK) Gonorrhoea Vaccine Gets FDA Fast Track Tag
by Zacks Equity Research
The FDA grants fast-track designation to GSK's investigational gonorrhoeae vaccine candidate. The grant enables GSK to seek expedited review for a potential FDA filing of the vaccine.
Gilead (GILD) Breast Cancer Drug Gets Positive CHMP Opinion
by Zacks Equity Research
Gilead's breast cancer drug Trodelvy gets positive CHMP opinion for a second indication in Europe.
AbbVie (ABBV) Gets CHMP Positive Opinion for Atogepant Approval
by Zacks Equity Research
AbbVie (ABBV) receives a positive recommendation from the European Union's medicinal products committee for the approval of its migraine treatment candidate, atogepant.
Novo Nordisk (NVO) Posts Upbeat Once-Weekly Insulin Icodec Data
by Zacks Equity Research
Novo Nordisk (NVO) announces encouraging new data from its late-stage ONWARDS 1 and 3 studies on once-weekly basal insulin icodec against once-daily comparators at 52 and 26 weeks, respectively.
Amylyx (AMLX) Down on Negative CHMP Opinion for ALS candidate
by Zacks Equity Research
Amylyx's (AMLX) shares plunge on getting a negative opinion from the Committee for Medicinal Products for Human Use for the marketing authorization of AMX0035, used to treat amyotrophic lateral sclerosis.
Pfizer's (PFE) Litfulo Receives FDA Nod for Alopecia Areata
by Zacks Equity Research
Pfizer's (PFE) Litfulo becomes the first kinase inhibitor approved for treating severe alopecia areata in adolescents, following FDA's approval.
Zacks.com featured highlights Toll Brothers, Walmart, Caterpillar, W.W. Grainger and Novartis
by Zacks Equity Research
Toll Brothers, Walmart, Caterpillar, W.W. Grainger and Novartis have been highlighted in this Screen of The Week article.
Gilead Sciences (GILD) Announces Positive HDV Treatment Data
by Zacks Equity Research
Gilead Sciences, Inc. (GILD) announces data on Hepcludex that reinforces the potential of bulevirtide as an effective and well-tolerated treatment for chronic HDV after 96 weeks.
Sarepta (SRPT) Gets FDA's Accelerated Nod for DMD Gene Therapy
by Zacks Equity Research
Following FDA???s approval, Sarepta's (SRPT) Elevidys becomes the first gene therapy for treating DMD.
5 Dividend Growth Stocks to Buy for Gains in the Second Half
by Sweta Killa
Toll Brothers (TOL), Walmart (WMT), Caterpillar (CAT), W.W. Grainger (GWW) and Novartis (NVS) could be compelling picks heading into the second half of the year.
bluebird's (BLUE) Gene Therapy for SCD Gets Priority Review
by Zacks Equity Research
bluebird's (BLUE) gene therapy lovotibeglogene autotemcel gets Priority Review in the United States for sickle cell disease.
Lilly (LLY) Gets FDA Nod for Pediatric Use of Diabetes Drugs
by Zacks Equity Research
Following FDA's label expansion approval, Lilly's (LLY) Jardiance and Synjardy are the first SGLT2 inhibitors approved for use in children aged 10 years and older with type 2 diabetes.
FDA Expands Pfizer's (PFE) Talzenna Label in Prostate Cancer
by Zacks Equity Research
Following FDA's label-expansion approval, Pfizer's (PFE) Talzenna is the first PARP inhibitor approved in combination with existing standard of care for treating HRR gene-mutated mCRPC.